Skip to main
NTRA
NTRA logo

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 25 analyst ratings
Buy
Strong Buy 36%
Buy 60%
Hold 4%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc is positioned for a positive financial trajectory due to significant gross margin (GM) expansion, driven by a strong clinical volume growth of its Signatera test, with a projected 60% increase in 2024 alongside rising average selling prices (ASPs) resulting from enhanced payor coverage. The company's gross margins have notably improved from the low 40s to approximately 60%, facilitated by a mix of higher-priced tests, increased reimbursement rates, and more recognized prices per test, indicating a robust operational framework for sustained growth. Furthermore, Natera's strategic advancements in its molecular residual disease (MRD) portfolio and its leadership in non-invasive prenatal testing (NIPT) place it advantageously within a substantial market opportunity, reinforcing its ability to navigate the evolving landscape of cancer screening and diagnostics.

Bears say

Natera's financial outlook appears negative primarily due to weaker-than-expected volume performance in the fourth quarter, compounded by disruptions from electronic medical record (EMR) integration and seasonal factors. The company's 2025 revenue guidance falls short of consensus estimates by approximately $28.3 million at the midpoint, indicating potential challenges in achieving profitability, especially if payors reduce or eliminate reimbursement for its products and services. Additionally, margin erosion is expected due to decreasing average selling prices (ASP) of Panorama and ongoing pricing pressures from expanding payor networks, which could further impact the company's revenue trajectory.

Natera (NTRA) has been analyzed by 25 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 60% recommend Buy, 4% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 25 analysts, Natera (NTRA) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $151.04, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $151.04, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.